To evaluate the results of radiotherapy and the prognostic factors affecting local control in nonextremity Ewing sarcomas.
Methods
Between 1995 and 2011, 44 patients with nonextremity Ewing sarcomas were treated with radiotherapy. Tumor localizations were pelvis in 23, spine in 13, thoracic region in 5, and cranium in 3 patients. Tumor size was ≥8 cm in 56.8% of patients. Distant metastases were present in 19 of the patients at the time of diagnosis (43.1%). All patients were treated with 12 weeks of neoadjuvant chemotherapy followed by surgery and radiotherapy (45-54 Gy) or radiotherapy alone (54-64.8 Gy). Radiotherapy was applied due to microscopic residue (R1) in 5 patients after the operation and macroscopic tumor in 39 patients (macroscopic residue [R2] and nonresectable tumor).
Results
Median follow-up was 49 months (range 9-195). Local failures developed in 7 patients (15.9%) and local control at 5 years was 81.4%. Local recurrence was detected in 6 patients (6/38) who did not have residual tumor after RT. Progression was detected in 1 patient (1/6) who had residual tumor. All those patients with local failure experienced further distant metastases. Possible prognostic factors such as age (≤17 vs >17), tumor localization, tumor volume (≤8 cm vs >8 cm), and M status at diagnosis (0 vs 1) were not related to local control.
Conclusions
Radiotherapy, either alone or adjuvant to surgery, provides local control in 80% of nonextremity Ewing sarcomas and plays an important role in treatment.
YockTIKrailoMFryerCJ; Children's Oncology Group. Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children's Oncology Group. J Clin Oncol2006;24 (24):3838–3843
2.
SchuckAAhrensSPaulussenMLocal therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys2003;55 (1):168–177
3.
SailerSLHarmonDCMankinHJTrumanJTSuitHDEwing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys1988;15 (1):43–52
4.
WilkinsRMPritchardDJBurgertEOJrUnniKKEwing's sarcoma of bone. Experience with 140 patients. Cancer1986;58 (11):2551–2555
5.
DonaldsonSSTorreyMLinkMP; Pediatric Oncology Group. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Int J Radiat Oncol Biol Phys1998;42 (1):125–135
6.
PuriAGuliaAJambhekarNALaskarSResults of surgical resection in pelvic Ewing's sarcoma. J Surg Oncol2012;106 (4):417–422
7.
BarbieriEEmilianiEZiniGCombined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys1990;19 (5):1165–1170
8.
CarrieCMascardEGomezFNonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology. Med Pediatr Oncol1999;33 (5):444–449
9.
WunderJSPaulianGHuvosAGHellerGMeyersPAHealeyJHThe histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am1998;80 (7):1020–1033
10.
VerstraeteKLLangPBone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol2000;34 (3):229–246
11.
EvansRGNesbitMEGehanEAMultimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol1991;9 (7):1173–1180
12.
HoffmannCAhrensSDunstJPelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer1999;85 (4):869–877
13.
BacciGFerrariSMercuriMMultimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol2003;25 (2):118–124
14.
ThomasIHColeWGWatersKDMenelausMBFunction after partial pelvic resection for Ewing's sarcoma. J Bone Joint Surg Br1987;69 (2):271–275
15.
EvansRNesbitMAskinFLocal recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. Int J Radiat Oncol Biol Phys1985;11 (1):129–136
16.
BurgersJMOldenburgerFde KrakerJEwing's sarcoma of the pelvis: changes over 25 years in treatment and results. Eur J Cancer1997;33 (14):2360–2367
17.
AraiYKunLEBrooksMTEwing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys1991;21 (6):1501–1508
18.
CapannaRToniASudaneseAMcDonaldDBacciGCampanacciMEwing's sarcoma of the pelvis. Int Orthop1990;14 (1):57–61
19.
YangRSEckardtJJEilberFRSurgical indications for Ewing's sarcoma of the pelvis. Cancer1995;76 (8):1388–1397
20.
IndelicatoDJKeoleSRShahlaeeAHImpact of local management on long-term outcomes in Ewing tumors of the pelvis and sacral bones: the University of Florida experience. Int J Radiat Oncol Biol Phys2008;72 (1):41–48
21.
BedettiBWiebeKRanftALocal Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial. Ann Surg Oncol2015;22 (9):2853–2859
22.
CaseyDLMeyersPAAlektiarKMEwing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol2014;113 (2):248–253
23.
LaTHMeyersPAWexlerLHRadiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys2006;64 (2):544–550
24.
BacciGForniCLonghiALong-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer2004;40 (1):73–83
25.
WunderJSPaulianGHuvosAGHellerGMeyersPAHealeyJHThe histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am1998;80 (7):1020–1033
26.
KrasinMJRodriguez-GalindoCBillupsCADefinitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys2004;60 (3):830–838
27.
ChoiYLimDHLeeSHRole of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors. Cancer Res Treat2015
28.
GöbelVJürgensHEtspülerGPrognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol1987;113 (2):187–191
29.
RödlRWHoffmannCGoshegerGLeidingerBJürgensHWinkelmannWEwing's sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol2003;83 (3):154–160
30.
OwensCAbbottLSGuptaAAOptimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs2013;15 (6):473–492
31.
JiangLTaoCHeAPrognostic significance of p53 expression in malignant bone tumors: a meta-analysis. Tumour Biol2013;34 (2):1037–1043
32.
JuergensHDawNCGeoergerBPreliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol2011;29 (34):4534–4540
33.
PappoASPatelSRCrowleyJR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol2011;29 (34):4541–4547
34.
López-GuerreroJAPellínANogueraRCardaCLlombart-BoschAMolecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest2001;81 (6):803–814
35.
HuangH-YIlleiPBZhaoZEwing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol2005;23 (3): 548–558
36.
MaitraARobertsHWeinbergAGGeradtsJAberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med2001;125 (9):1207–1212
37.
SubbiahVBrownREJiangYMorphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms’ tumor(WT1). PLoS ONE2013; 8 (7):e68985
